Drug Profile
Research programme: central nervous system disorder therapies - (now Teva Pharmaceutical Industries)/Ogeda
Alternative Names: GPCRs - Teva Pharmaceutical Industries/OgedaLatest Information Update: 18 May 2017
Price :
$50
*
At a glance
- Originator Cephalon; Euroscreen
- Developer Cephalon
- Class Small molecules
- Mechanism of Action G protein-coupled receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued CNS disorders
Most Recent Events
- 16 May 2017 Ogeda has been acquired by and became a wholly-owned subsidiary of Astellas Pharma
- 19 Oct 2016 Euroscreen is now called Ogeda
- 11 Jan 2010 Discontinued - Preclinical for CNS disorders in Belgium (unspecified route)